Partnering Success

Immunovaccine is pleased to announce that it has signed partnership agreements with:

National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), to formulate potential vaccines for HIV and malaria. The NIH is the largest health research government agency in the US.
La Jolla Institute for Allergy & Immunology (LIAI) to apply DepoVax™ vaccine delivery system to develop vaccines against seasonal and pandemic influenza.
Bioject Inc. to develop and improve needle-free delivery of vaccines
NRC /Institute of Biodiagnostics to develop novel methods to detect DepoVax™ effect on tumours
Atlantic Canada Opportunities Agency (ACOA) for funding and development of improved vaccine formulations
Defence Research & Development Canada to develop vaccines against anthrax and glanders
FIT Biotech, a Finland-based company, to advance a therapeutic HIV Vaccine
Scancell Ltd., a UK-based company to evaluate the potential to use IVT's DepoVax™ vaccine enhancement technology with Scancell's ImmunoBody(R) DNA vaccines
National Cancer Institute (NCI) to enhance the delivery of their cancer vaccine antigens